Multimodal therapy for primary ureteral small cell neuroendocrine carcinoma with high-grade urothelial component: case report and literature review

Yaqi Li, Yan Deng, Siwei Ma, Jie LiuFrontiers in Urology 2025 · DOI

TL;DR

This paper presents a groundbreaking case of a rare and aggressive ureteral small cell neuroendocrine carcinoma (SCNEC) treated successfully with a novel multimodal approach. By combining neoadjuvant chemotherapy with immune checkpoint inhibitors (ICIs) and radical surgery, the patient achieved a durable, recurrence-free survival, offering a beacon of hope for future treatment strategies in this challenging malignancy.

What Problem Does This Paper Address?

Primary small cell neuroendocrine carcinoma (SCNEC) of the ureter is an exceptionally rare and aggressive cancer, characterized by rapid growth and a poor prognosis. Standard treatment options are limited, and evidence for the efficacy of newer therapies like immune checkpoint inhibitors (ICIs) in this specific context is scarce. The paper addresses the critical need for effective treatment strategies for advanced ureteral SCNEC, particularly exploring the potential of combining chemotherapy, surgery, and immunotherapy.

Methods

The study details a multimodal treatment strategy applied to a single patient. The approach involved:

  • Neoadjuvant Chemotherapy: The patient received four cycles of etoposide and carboplatin chemotherapy before surgery. This is a standard chemotherapy regimen for SCLC, but its application in ureteral SCNEC is novel.
  • Radical Surgery: A radical left nephroureterectomy with bladder cuff excision was performed, a standard surgical procedure for upper tract urothelial cancers.
  • Adjuvant Therapy: Following surgery, the patient received intravesical pirarubicin and six cycles of dual PD-1 blockade immunotherapy (toripalimab and vedicitumab). This combination of immunotherapy and intravesical treatment is a novel aspect of the strategy.
  • Histopathology and Immunohistochemistry: These were crucial for confirming the diagnosis of SCNEC with a high-grade urothelial component and assessing tumor response (e.g., Ki67 index reduction).
  • Imaging: CT and FDG-PET/CT were used for initial staging, monitoring treatment response, and surveillance.

Datasets

Not discussed in the paper. The study is a case report and literature review, not based on a dataset of multiple patients or a benchmark dataset.

Key Insights and Ideas

  • Synergistic Efficacy of Multimodal Therapy: The most significant insight is the apparent synergy between neoadjuvant chemotherapy, radical surgery, and adjuvant immunotherapy in achieving a remarkable response in a highly aggressive cancer.
  • Potential of ICIs in Ureteral SCNEC: The success of PD-1 blockade in this case suggests that ICIs, which have shown promise in urothelial carcinoma (UC), may also be effective against the UC component within mixed SCNEC tumors.
  • Importance of the Urothelial Component: The paper highlights that the presence of a high-grade urothelial carcinoma component might contribute significantly to the observed immunotherapy benefit, as UC is known to respond well to PD-1/PD-L1 inhibitors.
  • Early Immunotherapy Use: The study underscores the potential benefit of integrating ICIs earlier in the treatment course, not just as a last resort.
  • Biomarker-Guided Strategies: The authors emphasize the need for further research into biomarkers that can predict response to immunotherapy in SCNEC.

Key Results

  • Tumor Regression: Post-neoadjuvant chemotherapy imaging showed a 60% reduction in tumor size.
  • Pathological Response: Surgical pathology confirmed R0 resection (complete removal of the tumor) with marked tumor regression. The Ki67 proliferation index, initially >75%, decreased to 40% post-treatment.
  • Disease-Free Survival: The patient remained disease-free at a 12-month follow-up, demonstrating a durable response.
  • Histological Confirmation: The tumor was confirmed to be high-grade urothelial carcinoma with small cell neuroendocrine differentiation, with the neuroendocrine component estimated to be approximately 70%.

Limitations and Future Work

  • Single-Case Study: The primary limitation is that this is a case report of a single patient. The findings, while promising, cannot be generalized without larger studies.
  • Rarity of the Disease: The extreme rarity of ureteral SCNEC makes conducting large-scale clinical trials challenging.
  • Need for Further Research: The authors strongly advocate for more research into:
  • Early immunotherapy use in advanced ureteral SCNEC.
  • Biomarker-guided therapeutic strategies to personalize treatment.
  • Exploring potential molecular targets (e.g., C-kit, EGFR, BCL2, CD56) for ureteral SCNEC, drawing parallels from prostatic SCNEC.
  • Optimizing treatment sequences and monitoring for long-term outcomes.
  • Radiotherapy Caution: The paper notes caution regarding combining radiotherapy with immunotherapy due to the risk of hyperprogression, suggesting careful patient selection and monitoring.

Summary updated

Abstract

Primary small cell neuroendocrine carcinoma (SCNEC) of the ureter is an exceptionally rare and aggressive malignancy, characterized by rapid progression and poor prognosis. Evidence regarding treatment with immune checkpoint inhibitors (ICIs) combined with neoadjuvant chemotherapy remains limited. We report the first documented case of ureteral SCNEC treated with a multimodal strategy incorporating programmed death-ligand 1 (PD-L1) inhibitors. A 57-year-old woman presented with a 15-day history of gross hematuria and 4 days of progressive left flank pain. Imaging revealed a left distal ureteral mass with hydronephrosis and suspected iliac lymphadenopathy. Stage IV high-grade urothelial carcinoma with small cell neuroendocrine differentiation of the ureter with regional lymph node metastases, confirmed by histopathology and immunohistochemistry (synaptophysin+, CD56+, Ki67 >75%). The patient received four cycles of neoadjuvant etoposide plus carboplatin chemotherapy, followed by radical left nephroureterectomy with bladder cuff excision. Adjuvant therapy included intravesical pirarubicin and six cycles of dual PD-1 blockade with toripalimab and vedicitumab. Post-neoadjuvant imaging showed a 60% reduction in tumor size. Pathology revealed R0 resection with marked tumor regression (Ki67 reduced to 40%). No recurrence was observed at 12-month follow-up. This case demonstrates the potential efficacy of integrating ICIs with standard treatment for advanced ureteral SCNEC. The durable response observed underscores the need for further research into early immunotherapy use and biomarker-guided therapeutic strategies.
BibTeX
@inproceedings{li2025multimodal,
  author = {Yaqi Li and Yan Deng and Siwei Ma and Jie Liu},
  title = {{Multimodal therapy for primary ureteral small cell neuroendocrine carcinoma with high-grade urothelial component: case report and literature review}},
  booktitle = {Frontiers in Urology},
  year = {2025},
  doi = {10.3389/fruro.2025.1615270},
}
Figure